Literature DB >> 11229830

The inhibition of TNK-t-PA by C1-inhibitor.

T Sulikowski1, P A Patston.   

Abstract

TNK-t-PA is a recombinant mutant of tissue plasminogen activator that has a longer half-life and higher selectivity for fibrin than normal tissue plasminogen activator (t-PA). In addition, it is reported to be serpin resistant because of reduced inhibition by plasminogen activator inhibitor-1. In this study, we have investigated the inhibition of TNK-t-PA by the serpin C1-inhibitor. TNK-t-PA is inhibited with a second-order rate constant of 7.5 per mol/l per s compared with 4.5 per mol/l per s for t-PA. In both cases, the stoichiometry was close to 20, indicating that C1-inhibitor was predominantly a substrate for both forms of t-PA. The formation of cleaved C1-inhibitor was seen on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and the t-PA-C1-inhibitor (or TNK-t-PA-C1-inhibitor) complex seen on SDS-PAGE and by zymography. Although the rates of inhibition are very slow in vitro, the fact that in vivo formation of the t-PA-C1-inhibitor complex after infusion of t-PA has been well documented suggests that TNK-t-PA will also be inhibited by C1-inhibitor in vivo and, perhaps more importantly, could cause a significant reduction in C1-inhibitor concentration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11229830     DOI: 10.1097/00001721-200101000-00011

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

Review 1.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

Review 2.  Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.

Authors:  Paul Tanswell; Nishit Modi; Dan Combs; Thierry Danays
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema.

Authors:  Colm Farrell; Siobhan Hayes; Anurag Relan; Edwin S van Amersfoort; Rienk Pijpstra; C Erik Hack
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

4.  Patterns of C1-Inhibitor/Plasma Serine Protease Complexes in Healthy Humans and in Hereditary Angioedema Patients.

Authors:  Erika Kajdácsi; Zsófia Jandrasics; Nóra Veszeli; Veronika Makó; Anna Koncz; Dominik Gulyás; Kinga Viktória Köhalmi; György Temesszentandrási; László Cervenak; Péter Gál; József Dobó; Steven de Maat; Coen Maas; Henriette Farkas; Lilian Varga
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

5.  Inhibition of plasma kallikrein by a highly specific active site blocking antibody.

Authors:  Jon A Kenniston; Ryan R Faucette; Diana Martik; Stephen R Comeau; Allison P Lindberg; Kris J Kopacz; Gregory P Conley; Jie Chen; Malini Viswanathan; Niksa Kastrapeli; Janja Cosic; Shauna Mason; Mike DiLeo; Jan Abendroth; Petr Kuzmic; Robert C Ladner; Thomas E Edwards; Christopher TenHoor; Burt A Adelman; Andrew E Nixon; Daniel J Sexton
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

Review 6.  Assessing Plasmin Generation in Health and Disease.

Authors:  Adam Miszta; Dana Huskens; Demy Donkervoort; Molly J M Roberts; Alisa S Wolberg; Bas de Laat
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.